A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically confirmed cancer with evidence of advanced disease for which no other standard treatment is available
• ECOG Performance status of 0 to 2
• Adequate hematological, renal, and hepatic organ function
Locations
Other Locations
Germany
Fachklinik Hornheide
RECRUITING
Münster
Universitätsklinikum Würzburg
RECRUITING
Würzburg
Contact Information
Primary
Clinical Operations
clinicaltrials@kupando.com
+49 30 52 00 58 60 20
Time Frame
Start Date: 2026-04
Estimated Completion Date: 2028-12
Participants
Target number of participants: 21
Treatments
Experimental: Dose level 1
Experimental: Dose level 2
Experimental: Dose level 3
Experimental: Dose level 4
Experimental: Dose level 5
Experimental: Dose level 6
Experimental: Dose level 7
Related Therapeutic Areas
Sponsors
Leads: Kupando GmbH